10-Q: Vaxcyte Advances PCV Programs, Reports Q2 Losses

Vaxcyte, a clinical-stage vaccine company, reported increased net losses in Q2 2025 while strategically advancing its lead pneumococcal conjugate vaccine candidates and streamlining its early-stage pipeline.

Summary

• Vaxcyte is a clinical-stage vaccine innovation company focused on engineering high-fidelity vaccines for bacterial diseases, primarily broad-spectrum conjugate and novel protein vaccines.
• The company's primary activities include research and development, preclinical and clinical studies, manufacturing, intellectual property establishment, and capital raising.
• Net loss for the three months ended June 30, 2025, was $166.6 million, compared to $128.7 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $307.3 million, compared to $223.7 million for the same period in 2024.
• Research and development expenses increased by $62.7 million (47.7%) to $194.2 million for Q2 2025, and by $116.2 million (51.4%) to $342.3 million for the six months ended June 30, 2025, driven by increased development and manufacturing activities for PCV programs and headcount growth.
• General and administrative expenses increased by $10.6 million (49.2%) to $32.0 million for Q2 2025, and by $23.3 million (56.4%) to $64.7 million for the six months ended June 30, 2025, primarily due to headcount growth.
• Total other income, net, increased by $35.4 million (145.7%) to $59.6 million for Q2 2025, and by $56.0 million (128.0%) to $99.7 million for the six months ended June 30, 2025, mainly due to unrealized and realized foreign currency gains and higher interest income.
• As of June 30, 2025, cash, cash equivalents, and investments totaled $2.8 billion, with an accumulated deficit of $1.7 billion.
• The company paused advancement of VAX-A1 and VAX-GI beyond preclinical development to prioritize resources for the PCV franchise.
• Further development of VAX-PG was discontinued due to insufficient efficacy signals in preclinical data.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and has streamlined its pipeline by pausing/discontinuing some early-stage programs, this is offset by strong clinical progress for its lead PCV candidates (VAX-31 and VAX-24), including expanded FDA Breakthrough Therapy Designation for VAX-31 and positive Phase 1/2 data. The company also maintains a robust cash position, providing a long runway for operations. The strategic focus on the PCV franchise is a positive for resource allocation, despite the narrowing of the pipeline.

Positives

• VAX-31, a 31-valent PCV candidate, received an expanded FDA Breakthrough Therapy Designation (BTD) to include prevention of pneumonia caused by Streptococcus pneumoniae in adults, in addition to prevention of Invasive Pneumococcal Disease (IPD).
• Positive topline results from the VAX-31 adult Phase 1/2 study showed it was well tolerated, had a safety profile similar to PCV20, and demonstrated robust OPA immune responses for all 31 serotypes at all doses studied.
• At the VAX-31 High dose, average OPA immune responses were greater for 18 of 20 serotypes compared to PCV20, with seven achieving statistically higher immune responses.
• For all 11 incremental serotypes unique to VAX-31, all three doses met superiority criteria.
• VAX-24 infant Phase 2 dose-finding study showed VAX-24 was well-tolerated and demonstrated a safety profile similar to PCV20 across all doses.
• VAX-24 Mid dose met target precedent Phase 2 non-inferiority criteria for 20 of 24 serotypes overall post-dose 3 in infants.
• VAX-24 elicited robust memory responses across all doses for all serotypes, evidenced by the boost demonstrated post-dose 4 for IgG responses.
• The company maintains a strong cash, cash equivalents, and investments position of $2.8 billion as of June 30, 2025.
• Dr. Olivier Brandicourt, a veteran biopharmaceutical executive, was appointed to the Board of Directors in May 2025, bringing significant commercial strategy and execution experience in the global vaccine market.
• Chris Griffith joined as Chief Business and Strategy Officer in July 2025, a newly expanded role to ensure strong cross-functional alignment and execution for late-stage programs.

Negatives

• Net loss increased significantly to $166.6 million for Q2 2025 and $307.3 million for the six months ended June 30, 2025, compared to prior periods.
• Research and development expenses increased substantially due to intensified development and manufacturing activities.
• The advancement of VAX-A1 (Group A Streptococcus) and VAX-GI (dysentery and shigellosis) programs has been paused beyond preclinical development to prioritize the PCV franchise.
• Further development of VAX-PG was discontinued due to insufficient efficacy signals in preclinical data, despite an acceptable safety profile.
• The company has incurred significant net losses since inception, with an accumulated deficit of $1.7 billion as of June 30, 2025, and currently has no product revenue.

Risks

• The company is in clinical or preclinical stages of vaccine development with a limited operating history and no products approved for commercial sale, making future viability difficult to evaluate.
• Substantial additional funding will be required to finance operations, which may not be available on acceptable terms, potentially forcing delays, reductions, or termination of development programs.
• The approach to vaccine discovery and development is based on novel, unproven technologies (cell-free protein synthesis platform), which may expose the company to unforeseen risks, require process modifications, and make predicting development time and cost difficult.
• Vaccine candidates are in clinical or preclinical stages and may fail in development or suffer delays, materially and adversely affecting commercial viability.
• The U.S. Food and Drug Administration (FDA) may disagree with the regulatory plan, potentially leading to failure in obtaining regulatory approval.
• Business is highly dependent on the success of PCV candidates; failure to successfully develop, obtain approval for, and commercialize them would be significantly harmful.
• Primary competitors have significantly greater resources and experience, potentially making it difficult to successfully develop and commercialize vaccine candidates or resulting in others commercializing products first.
• The company may not be successful in using its cell-free protein synthesis platform to expand its pipeline and develop marketable products.
• Reliance on third-party manufacturing and supply partners, including Lonza, for raw materials and manufacturing exposes the company to risks of delays, interruptions, or failure to comply with regulatory requirements.
• The FDA regulatory approval process is lengthy and time-consuming, potentially leading to significant delays in clinical development and regulatory approval.
• Changes in funding for, or staffing at, the FDA and other government agencies could prevent timely development or commercialization of new products.
• Inability to obtain and maintain patent protection for technology and products, or insufficient breadth of protection, may hinder effective competition.
• Interim topline and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• Even if vaccine candidates receive marketing approval, they may not gain market acceptance among regulators, advisory boards, physicians, patients, and third-party payors.
• The company currently has no marketing and sales organization and no experience in marketing products, requiring significant investment or reliance on third parties.
• Conducting research and clinical trials abroad and marketing internationally exposes the company to additional risks, including differing regulatory requirements, tariffs, and foreign currency fluctuations.
• Highly dependent on key personnel; inability to retain or recruit qualified personnel may hinder business strategy implementation.
• Rapid growth may lead to difficulties in management and operational expansion.
• Obtaining regulatory approval in one jurisdiction does not guarantee success in others.
• Revenue from any catch-up opportunity may decline over time as more of the patient population is vaccinated.
• Information technology systems or those of third parties may be compromised, leading to adverse consequences.
• Use of artificial intelligence in operations could result in reputational or competitive harm and legal or regulatory liability.
• Natural or man-made disasters or business disruptions could seriously harm future revenue and financial condition.
• Product liability lawsuits could lead to substantial liabilities and limit commercialization.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or improper activities.
• Changes in tax laws or tax rulings could affect financial position.
• Ability to utilize Net Operating Loss (NOL) carryforwards and other tax attributes may be limited.
• Insurance policies may be inadequate, exposing the company to unrecoverable risks.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• Geoeconomic tensions, protectionist policies, and trade disputes could adversely affect the business.
• Financial results may fluctuate from quarter to quarter and year to year, making them difficult to predict.
• Failure to maintain proper and effective internal control over financial reporting could impair accurate and timely financial statements.
• Reported financial results may be adversely affected by changes in U.S. GAAP.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• Claims for indemnification by directors and officers may reduce available funds.

Future Outlook

Vaxcyte plans to initiate the VAX-31 adult Phase 3 pivotal, non-inferiority study in the fourth quarter of 2025, with topline data expected in 2026. Remaining Phase 3 studies are planned for 2025 and 2026, with data announcements in 2026 and 2027. A Biologics License Application (BLA) submission is planned shortly after the completion of the last Phase 3 study. The company expects to announce the balance of VAX-24 infant Phase 2 data by the end of 2025. The modified VAX-31 infant Phase 2 study is expected to proceed with enrollment by the end of Q3 2025, with topline data from the primary immunization series and booster dose by the end of the first half of 2027. Following the VAX-31 infant study readout, a Phase 3 program with an optimized dose formulation of VAX-24 or VAX-31 is planned. The company anticipates continued increases in operating expenses and capital expenditures as it advances vaccine candidates, scales manufacturing, and pursues regulatory approvals.

Management Comments

• We are incorporating the FDA's input to finalize the Phase 3 program designed to validate VAX-31 as the potential new standard-of-care adult PCV.
• As part of our continued focus on strategic capital deployment, we are prioritizing resources toward our PCV franchise.
• We have paused the advancement, beyond preclinical development, of VAX-A1 and VAX-GI, while remaining confident in their potential and preserving the option to advance the programs in the future.
• We discontinued further development of VAX-PG, which demonstrated an acceptable safety profile but not sufficient efficacy signals to warrant further investment.

Industry Context

The global pneumococcal vaccine market is approximately $8 billion, dominated by a few multinational pharmaceutical corporations like Pfizer, Merck, GSK, and Sanofi. Vaxcyte's broad-spectrum PCV candidates aim to address serotype replacement, a phenomenon where non-covered strains increase in incidence after widespread vaccination with existing vaccines. Competitors are also developing higher-valent PCVs, with Pfizer developing PCV25 and a 30-plus valent candidate, Merck having PCV15 and PCV21 approved, and Sanofi/SK Chemicals advancing a 21-valent PCV. GSK is also focusing on a 30-plus valent candidate.

Comparison to Industry Standards

• VAX-31 is designed to increase coverage to approximately 95% of IPD circulating in adults aged 50 and older in the United States, potentially providing an incremental 14-34% coverage over current standard-of-care adult PCVs like Prevnar 20 (PCV20).
• VAX-31 is designed to cover approximately 92% of IPD and 93% of acute otitis media due to Streptococcus pneumoniae in children under five years of age in the United States.
• VAX-24 is a 24-valent PCV candidate designed to cover more serotypes than any pneumococcal infant vaccine currently on the market.
• In the VAX-31 adult Phase 1/2 study, at the High dose, average OPA immune responses were greater for 18 of 20 serotypes compared to PCV20, with seven achieving statistically higher immune responses.
• For all 11 incremental serotypes unique to VAX-31 (not in PCV20), all three doses met superiority criteria.
• The VAX-24 Mid dose in infants met target precedent Phase 2 non-inferiority criteria for 20 of 24 serotypes overall, compared to PCV20.

Management Changes

Legal Proceedings

• The company is not presently a party to any legal proceedings that would have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• Commercial Manufacturing and Supply Agreement with Lonza for manufacturing key components for the PCV franchise.
• Development and Manufacturing Services Agreements with Lonza (2022 Lonza DMSA and 2023 Lonza DMSA) for manufacturing process development and clinical supply of PCV candidates.
• Amended and Restated License Agreement with Sutro Biopharma for exclusive, worldwide, royalty-bearing license under Sutro Biopharma's patents and know-how relating to cell-free expression of proteins for vaccine compositions.
• Supply Agreement with Sutro Biopharma for purchasing extract and custom reagents for manufacturing non-clinical and certain clinical supply of vaccine compositions.
• Option Agreement with Sutro Biopharma, which was exercised, granting rights to independently manufacture and/or source cell-free extract and develop improvements.
• Manufacturing Rights Agreement with Sutro Biopharma, effective upon option exercise, granting exclusive rights to develop, improve, and manufacture cell-free extract for vaccine candidates.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility, and long-term value creation tied to successful vaccine commercialization.
• Employees: Headcount growth in R&D and G&A functions, stock-based compensation as an incentive, but also potential for shifts in program focus (e.g., VAX-A1, VAX-GI, VAX-PG).
• Customers/Patients: Potential for new, broad-spectrum pneumococcal vaccines (VAX-31, VAX-24) to address unmet medical needs and improve protection against bacterial diseases.
• Suppliers/Contract Manufacturers (e.g., Lonza, Sutro Biopharma): Continued reliance on third parties for manufacturing and supply, with significant purchase commitments, indicating ongoing business for these partners.
• Creditors: Increased net losses and substantial capital requirements indicate continued reliance on financing, but a strong cash position provides a buffer.

Next Steps

• Initiate the VAX-31 adult Phase 3 pivotal, non-inferiority study in the fourth quarter of 2025.
• Announce topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 pivotal study in 2026.
• Initiate remaining VAX-31 adult Phase 3 studies in 2025 and 2026, with data announcements in 2026 and 2027.
• Submit a Biologics License Application (BLA) shortly following the completion of the last VAX-31 adult Phase 3 study.
• Announce the balance of the VAX-24 infant Phase 2 dose-finding study data, including final safety, full post-dose 3 OPA, and full post-dose 4 IgG and OPA data, by the end of 2025.
• Proceed with enrollment in the modified VAX-31 infant Phase 2 randomized, dose-finding study by the end of the third quarter of 2025.
• Announce topline safety, tolerability, and immunogenicity data for the VAX-31 infant Phase 2 study from both the primary three-dose immunization series and booster dose by the end of the first half of 2027.
• Pending the VAX-31 infant study readout, plan to initiate a Phase 3 program with an optimized dose formulation of VAX-24 or VAX-31 for the pediatric population.

Key Dates

Recommendation

Vaxcyte demonstrates significant progress in its core pneumococcal conjugate vaccine (PCV) programs, particularly with VAX-31 receiving expanded Breakthrough Therapy Designation and positive Phase 1/2 adult data, and VAX-24 showing promising infant Phase 2 results. The company's strategic decision to prioritize the PCV franchise by pausing other early-stage programs, while leading to increased losses in the short term due to R&D scale-up, is a prudent allocation of resources given the large market opportunity. The substantial cash reserves provide a strong financial runway. However, the company remains in a clinical stage with no commercial products, faces intense competition, and is subject to inherent risks of clinical trial success, regulatory approval, and manufacturing scale-up. The increased net losses, while expected for a development-stage company, highlight the significant burn rate. Therefore, a 'hold' recommendation is appropriate, acknowledging the strong potential of the lead assets and solid financial position, but also the high-risk nature and long timeline to commercialization.

Keywords

Vaccine, Pneumococcal Conjugate Vaccine, PCV, VAX-31, VAX-24, Biotechnology, Clinical Stage, FDA Breakthrough Therapy, Cell-free protein synthesis, Infectious Disease, Biologics, Lonza, Sutro Biopharma